No abstract available.
Nocturnal Enuresis*

No abstract available.
Nocturnal Enuresis*

Nocturnal enuresis has been recognized as an adverse effect of clozapine treatment. We reported 3 chronic schizophrenic patients who had showed nocturnal enuresis following clozapine treatment. Oxybutynin hydrochloride on clozapine-induced enuresis was very effective in 3 patients. The dose in our patients was 5 to 10mg/day. This medication was well tolerated. It is suggested that oxybutynin hydrochloride is a effective therapeutic option in clozapine-induced nocturnal enuresis.
Clozapine* ; Enuresis ; Humans ; Nocturnal Enuresis* ; Schizophrenia

PURPOSE: The aim of this study, to investigate whether there is any association between enuresis in childhood and nocturnal polyuria syndrome (NPS) in adult life. METHODS: The study consisted of thirty five patients with nocturnal polyuria, and thirty five healthy people without nocturnal polyuria in adult life, were asked to assess their enuresis in childhood. RESULTS: There was a history of enuresis in childhood in 18 (51.42%) of 35 of men with nocturnal polyuria and in 4 (11.42%) of 35 without nocturnal polyuria. Enuresis in childhood was significantly more common in men with nocturnal polyuria than without nocturnal polyuria. The difference was significant (P<0.0001). The prevalence of enuresis in the nocturnal polyuria (51.42%) was more than two-fold higher than reported prevalence in general populations. CONCLUSIONS: The results of this study suggest that the history of enuresis in childhood seems to increase the risk of having NPS in adult life. This relationship should be taken into account in the evaluation of men with complaints from NPS in adult life and the possible common pathophysiology should be considered in the treatment planning.
Adult ; Child ; Enuresis ; Humans ; Male ; Nocturnal Enuresis ; Polyuria ; Prevalence

BACKGROUND: We examined the usefulness of urine osmolality, as a predictive factor in the treatment of monosymptomatic nocturnal enuresis (NE) with combination therapy of imipramine and desmopressin. METHODS: From May 2014 to April 2015, 59 monosymptomatic NE patients participated in this study. Early morning urine osmolality was measured at 1 week and 1 day before combination therapy of imipramine and desmopressin, and at 1 week and 2 weeks after therapy. The response to combination therapy was evaluated at 3 months after treatment. The mean period of combination therapy was 6.4+/-4.2 weeks. Therapeutic response was classified as complete (0-1 wet night/week), partial (over 50% reduction of night) and non-responders (less than 50% reduction of night). RESULTS: The cumulative rate of the complete and partial responders was 76.3%. Among the 3 groups, the statistically lowest value of pre-treatment urine osmolality was observed in the complete responder group (p<0.001). Urine osmolality increased in all groups after treatment, however, statistically the greatest difference between pre and post-treatment urine osmolality was observed in the complete responder group (p=0.024). No serious side effects were observed. CONCLUSION: Early morning urine osmolality and change of urine osmolality between pre and post-treatment have predictive values in the response to combined imipramine and desmopressin for treatment of monosymptomatic NE.
Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine* ; Nocturnal Enuresis* ; Osmolar Concentration*

PURPOSE: To investigate the correlation between functional bladder capacity, first morning urine osmolality, daytime voiding symptoms, and severity of nocturnal enuresis. MATERIALS AND METHODS: We assessed a total of 101 children with nocturnal enuresis (mean age, 7.7+/-2.3 years). Patients were divided into three groups according to the severity of enuresis: (1) one to six episodes per week (46 cases, 45.5%), (2) one episode every day (29 cases, 28.7%), and (3) multiple episodes every day (26 cases, 25.8%). Baseline parameters were obtained from frequency volume charts for 2 days, first morning urine osmolality, and a questionnaire for the presence of frequency, urgency, and daytime incontinence. RESULTS: The severity of enuresis increased with younger age (p=0.037) and reduced functional bladder capacity (p=0.007) and daytime symptoms of frequency and daytime incontinence (p=0.012, p=0.036). No statistical difference in urine osmolality or urgency was found among the three groups. Both reduced functional bladder capacity and low urine osmolality increased according to the severity of enuresis (p=0.012). CONCLUSIONS: In children with nocturnal enuresis, severity was increased by younger age, reduced functional bladder capacity, and the presence of daytime voiding symptoms of frequency and daytime incontinence. The incidence of small functional bladder capacity was increased in children with everyday wetting, and the incidences of both small functional bladder capacity and low urine osmolality were increased in children with everyday multiple wetting.
Child ; Enuresis ; Humans ; Incidence ; Nocturnal Enuresis ; Osmolar Concentration ; Urinary Bladder

The treatment of choice for primary nocturnal enuresis (PNE) in Korea remains imipramine which has proven to be effective in approximately 50 to 80%, but it is an antidepressant with toxic side effects and risk of overdose. Recently desmopressin (DDAVP, 1-desamino-8-Darginine-vasopressin) has been introduced for the treatment and its effect has been promising in many reports. To find the efficacy and safety of intranasal desmopressin, we evaluated the results of therapy in 48 enuretic children (34 boys and 14 girls). Mean age was 9.8 years (range 5-16). All the children were evaluated at least 3 months after the treatment with intranasal desmopressin. The overall response rate was 83.3%. The number of wet night per week before and after intranasal desmopressin treatment was 6.42 and 1.83 nights per week respectively. No side effects were observed. These data shows that the intranasal desmopressin therapy is effective and safe for the treatment of PNE.
Child ; Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine ; Korea ; Nocturnal Enuresis*

Humans ; Magnetic Resonance Imaging ; Nocturnal Enuresis/diagnostic imaging*

Congenital bladder diverticulum usually occurs in areas where the muscle is inadequately formed, typically at the ureterovesical junction, or between bundles of hypertrophied muscle. Congenital bladder diverticulum might be missed in excretory urography, especially in case that primary symptom is not so severe to justify further invasive studies. Physicians should not neglect voiding symptoms in pediatric patients and should have high suspicion of congenital diseases. We report a case of rare congenital bladder diverticulum, misdiagosed as non-neurogenic neurogenic bladder, presenting as nocturnal enuresis, daytime frequency and post-voiding residual urine sensation without vesicoureteral reflux or outlet obstruction.
Diverticulum* ; Enuresis ; Humans ; Nocturnal Enuresis ; Sensation ; Urinary Bladder* ; Urinary Bladder, Neurogenic* ; Urography ; Vesico-Ureteral Reflux

PURPOSE: We evaluated the additional effect of an enuresis alarm therapy for the partial responders to oral desmopressin in children with monosymptomatic nocturnal enuresis. MATERIALS AND METHODS: A total of 28 nocturnal enuretic children (male:female, 20:8), aged from 5 to 15 years old, were treated with oral desmopressin. After 10 weeks, the short-term effectiveness of oral desmopressin was evaluated. The full responders (enuretic episode< or =1 time/week) were treated with oral desmopressin only (group D). An additional enuresis alarm treatment was applied for the partial responders to the desmopressin treatment (enuretic episode>1 time/week) (group DA). The medication was continued until the patient showed complete night-time dryness for a whole month. We also followed the long-term responses of these two groups after all the treatments were finished. RESULTS: Fourteen patients were assigned to group A, and the other fourteen to group DA. There was no significant difference between the two groups with regard to mean age and number of wet nights per week before treatment. During the initial short-term follow-up, the mean wet nights per week decreased from 6.60 to 0.25 in group D, and from 5.60 to 2.35 in group DA (p<0.05). Ninety-two percent (13/14) of the patients achieved complete dryness in each group on the long-term follow-up. During the study period, the enuretic episodes recurred in one patient from each group. CONCLUSIONS: The addition of an enuresis alarm treatment for the partial responders to oral desmopressin showed an excellent response, with a similar long term cure rate as for the full responders. Therefore, an enuresis alarm treatment could be a reasonable second line modality for partial responders to oral desmopressin.
Adolescent ; Child* ; Deamino Arginine Vasopressin* ; Enuresis* ; Follow-Up Studies ; Humans ; Nocturnal Enuresis